OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phas…
| Métrica | OSE.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -1431.3% | -34.4% | -1396.9% |
| Net Margin | -1439.1% | -32.5% | -1406.6% |
| FCF Margin | -1303.3% | -12.6% | -1290.7% |
| ROE | -135.8% | -39.2% | -96.6% |
| ROA | -47.8% | -30.9% | -16.8% |
| Current Ratio | 1.28 | 2.73 | -1.45 |
| Debt / Equity | 0.79 | 0.28 | +0.51 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -47.8% | — |
| ✗Flujo de caja operativo positivo | −€34M | €48M |
| ✗Rentabilidad sobre activos al alza | -47.8% | 30.2% |
| ✓Caja operativa/activos supera al ROA | -43.2% | ROA -47.8% |
| ✓Menos deuda a largo plazo | 27.7% | 28.8% |
| ✗Mejor liquidez (ratio corriente) | 1.28 | 3.46 |
| ✓Sin aumentar el nº de acciones | 22M | 26M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.03 | 0.56 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -1303.3% |
| ✗ROCE > 10 % | -69.5% |
| ✗Ventas > 5 %/año (3 años) | -53.6% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 1299.4% |
OSE IMMUNOTHERAPEUTICS cotiza a 2.16 EUR y tiene una capitalización bursátil de €53M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud